The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS

Journal of Affective Disorders

Volumn 116, Issue 3, 2009, Pages 222-226

  Kelly, Tammas ^a   Lieberman, Daniel Z ^b  

^a The Depression and Bipolar Clinic of Colorado   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Bipolar disorder; Bipolar disorder NOS; Bipolar II treatment resistant depression; Manic depressive illness

Indexed keywords

ALENDRONIC ACID; ANTIARRHYTHMIC AGENT; LIOTHYRONINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR II DISORDER; BONE ATROPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; HEART ATRIUM FIBRILLATION; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRIVATE HOSPITAL; REMISSION; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIIODOTHYRONINE; YOUNG ADULT;

EID: 67349186895     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.12.010     Document Type: Article

References (35)

1. Akiskal H.S. The emergence of the bipolar spectrum:validation along clinical-epidemiologic and familial-genetic lines. Psychopharmacol. Bull. 40 (2007) 99-115
2. Akiskal H.S., Akiskal K.K., Lancrenon S., Hantouche E.G., Fraud J.P., Gury C., and Allilaire J.F. Validating the bipolar spectrum in the French National EPIDEP Study: overview of the phenomenology and relative prevalence of its clinical prototypes. J. Affect. Disord. 96 (2006) 197-205
3. American Society of Health-System Pharmacists. Levothyroxine sodium In AHFS Drug InformationBethesda, MD (2007) 3242-3245
4. American Society of Health-System Pharmacists. Liothyronine sodium In AHFS Drug InformationBethesda, MD (2007) 3246-3247
5. Bahls S.C., and de Carvalho G.A. The relation between thyroid function and depression: a review. Rev. Bras. Psiquiatr. 26 (2004) 41-49
6. Bartalena L., Pellegrini L., Meschi M., Antonangeli L., Bogazzi F., Dell'Osso L., Pinchera A., and Placidi G.F. Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Res. 34 (1990) 13-17
7. Bauer M.S., and Whybrow P.C. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch. Gen. Psychiatry 47 (1990) 435-440
8. Bauer M., Baur H., Berghofer A., Strohle A., Hellweg R., Muller-Oerlinghausen B., and Baumgartner A. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J. Affect. Disord. 68 (2002) 285-294
9. Bauer M., Fairbanks L., Berghofer A., Hierholzer J., Bschor T., Baethge C., Rasgon N., Sasse J., and Whybrow P.C. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J. Affect. Disord. 83 (2004) 183-190
10. Bauer M., London E.D., Rasgon N., Berman S.M., Frye M.A., Altshuler L.L., Mandelkern M.A., Bramen J., Voytek B., Woods R., Mazziotta J.C., and Whybrow P.C. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol. Psychiatry 10 (2005) 456-469
11. Benazzi F., and Akiskal H.S. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J. Affect. Disord. 73 (2003) 33-38
12. Chang K.D., Keck P.E., Stanton S.P., McElroy S.L., Strakowski S.M., and Geracioti T.D. Differences in thyroid function between bipolar manic and mixed states. Biol. Psychiatry 43 (1998) 730-733
13. Cleare A.J., McGregor A., and O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin. Endocrinol. (Oxf.) 43 (1995) 713-719
14. Cole D.P., Thase M.E., Mallinger A.G., Soares J.C., Luther J.F., Kupfer D.J., and Frank E. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am. J. Psychiatry 159 (2002) 116-121
15. Cowdry R.W., Wehr T.A., Zis A.P., and Goodwin F.K. Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch. Gen. Psychiatry 40 (1983) 414-420
16. Crismon M.L., Argo T.R., Bendele S.D., and Suppes T. Texas Medication Algorithm Project Procdural Manual, Bipolar Disorder Algorithms, Texas Department of State Health Services (2007)
17. Eskandari F., Martinez P.E., Torvik S., Phillips T.M., Sternberg E.M., Mistry S., Ronsaville D., Wesley R., Toomey C., Sebring N.G., Reynolds J.C., Blackman M.R., Calis K.A., Gold P.W., and Cizza G. Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167 (2007) 2329-2336
18. Haney E.M., Chan B.K., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., Orwoll E., and Bliziotes M.M. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167 (2007) 1246-1251
19. Heal D.J., and Smith S.L. The effects of acute and repeated administration of T3 to mice on 5-HT1 and 5-HT2 function in the brain and its influence on the actions of repeated eletroconvulsive shock. Neuropharmacology 27 (1998) 1239-1248
20. Hendrick V., Altshuler L., and Whybrow P. Psychoneuroendocrinology of mood disorders. The hypothalamic-pituitary-thyroid axis. Psychiatr. Clin. North Am. 21 (1998) 277-292
21. Karga H., Papapetrou P.D., Korakovouni A., Papandroulaki F., Polymeris A., and Pampouras G. Bone mineral density in hyperthyroidism. Clin. Endocrinol. (Oxf.) 61 (2004) 466-472
22. Leonard J.L., and Koehrle J. Intracellular pathways of iodothyronine metabolism. In: Braverman L.E., and Utiger R.D. (Eds). The Thyroid. A Fundamental and Clinical Text. 8th ed (2000), Williams & Wilkins, Philadelphia 136-171
23. Łojko D., and Rybakowski J. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J. Affect. Disord. 103 1 (2007) 253-256 (November)
24. Melton, L.J., III, Chrischilles, E.A., Cooper, C., Lane, A.W. and Riggs, B.L. (2005) How many women have osteoporosis? JBMR Anniversary Classic. JBMR, Volume 7, Number 9, 1992 J Bone Miner Res, 20, 886-92.
25. Misra M., Papakostas G.I., and Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry 65 (2004) 1607-1618 (quiz 1590, 1760-1.)
26. Oomen H.A., Schipperijn A.J., and Drexhage H.A. The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. Clin. Endocrinol. (Oxf.) 45 (1996) 215-223
27. Osler W. The Principles and Practice of Medicine (1901), D. Appleton and Company, New York, NY
28. Sachs G.S., and Thase M.E. Bipolar disorder therapeutics: maintenance treatment. Biol. Psychiatry 48 (2000) 573-581
29. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., and Docherty J.P. The expert consensus guideline series: medication treatment of bipolar disorder. Postgrad. Med. (2000) 1-104 (Spec No)
30. Singh N., and Hershman J.M. Interference with the absorption of levothyroxine. Curr. Opin. Endocrinol. Diabetes 10 (2003) 347-352
31. Soroko S.B., Barrett-Connor E., Edelstein S.L., and Kritz-Silverstein D. Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo Study. J. Bone Miner. Res. 9 (1994) 761-769
32. Sullivan G.M., Hatterer J.A., Herbert J., Chen X., Roose S.P., Attia E., Mann J.J., Marangell L.B., Goetz R.R., and Gorman J.M. Low levels of transthyretin in the CSF of depressed patients. Am. J. Psychiatry 156 (1999) 710-715
33. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., Crismon M.L., Ketter T.A., Sachs G.S., and Swann A.C. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66 (2005) 870-886
34. Vestergaard P., and Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid 13 (2003) 585-593
35. Vieta E., and Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 10 (2008) 163-178